Structure-guided design of peptidic ligand for human prostate specific antigen
β Scribed by MD Imtaiyaz Hassan; Vijay Kumar; Rishi K. Somvanshi; Sharmistha Dey; Tej P. Singh; Savita Yadav
- Book ID
- 105360728
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 404 KB
- Volume
- 13
- Category
- Article
- ISSN
- 1075-2617
- DOI
- 10.1002/psc.911
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Prostate specific antigen (PSA) is a member of kallikrein family having serine proteaseβlike activity and acts as a prognostic marker of prostate carcinoma. Various studies have been performed on inhibition of PSA and such targeting requires the identification of highly selective peptide inhibitors. PSA was purified from human seminal plasma by rapid and efficient methods, and binding studies for various peptides were carried out by fluorescence spectroscopy and SPR. The βSβ of PSA is predominated by hydrophobic residues, and hence many hydrophobic peptides were used to determine their binding affinity to PSA by fluorescence spectroscopy. We observed that LLFW, FFKW, and KFW binds strongly to PSA, among them LLFW showed strong binding. SPR also showed strong binding affinity of PSA toward peptides with hydrophobic and basic residues. Among the peptides used, FWYS showed dramatic increase in binding affinity (10^β10^ M). The peptides analyzed for binding studies, suggests that peptide with Trp residue along with basic or hydrophobic amino acids may be useful for designing specific inhibitors for PSA. The strong affinities of designed peptides for PSA can be a valuable tool for designing therapeutic agents for prostate carcinomas. Copyright Β© 2007 European Peptide Society and John Wiley & Sons, Ltd.
π SIMILAR VOLUMES
Prostate-specific antigen (PSA), a tissue-specific protein expressed by most adenocarcinomas of the prostate, might be a useful target for T-cell-mediated immunotherapy of prostate cancers. The current study examined whether it is possible to elicit human cytotoxic T lymphocytes (CTL) with specifici